

19 August 2024

**Futura Medical plc**  
**("Futura" or the "Company")**

**Notice of Results**

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will announce its unaudited results for the six months ended 30 June 2024 on Tuesday 10 September 2024.

The Company will be hosting a webinar for retail investors via the Investor Meet Company platform on 10 September 2024, at 9:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am BST the day before, or at any time during the live presentation.

Investors can register for the presentation via the following link: <https://www.investormeetcompany.com/futura-medical-plc/register-investor>

In addition, management will be hosting a webinar for analysts on 10 September 2024 at 11:00am BST. If you would like to register, please contact [futura@almastrategic.com](mailto:futura@almastrategic.com)

**Contacts:**

<b>Futura Medical plc</b>	James Barder Chief Executive Officer Angela Hildreth Finance Director and COO	<a href="mailto:investor.relations@futura-medical.com">investor.relations@futura-medical.com</a> +44 (0)1483 685 670 <a href="http://www.futura-medical.com">www.futura-medical.com</a>
<b>Panmure Liberum</b> Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0)20 3100 2000
<b>Stifel Nicolaus</b> <b>Europe Limited</b> Joint Broker	Alan Selby Ben Maddison	+44 (0)207 710 7600
<b>Alma Strategic</b> <b>Communications</b>	Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock	+44 (0)20 3405 0205 <a href="mailto:futura@almastrategic.com">futura@almastrategic.com</a>

**Notes to Editors:**

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lse.com](mailto:ms@lse.com) or visit [www.lse.com](http://www.lse.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOREQLFFZVLFBBL